Pharmacological properties of azelnidipine, a long-acting calcium channel blocker with high-affinity for vascular tissues (Part 1): Calcium-channel blocking actions in receptor binding and isolated blood vessel studies

Japanese Pharmacology and Therapeutics

Volumn 30, Issue 9, 2002, Pages 703-709

  Sada, Toshio ^a   Mizuno, Makoto ^a   Miyama, Chizuru ^a   Wada, Yoshihiro ^a   Koike, Hiroyuki ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; AZELNIDIPINE; BENIDIPINE; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHLORIDE; NICARDIPINE; NITRENDIPINE;

ANIMAL TISSUE; ANTIHYPERTENSIVE THERAPY; AORTA; ARTICLE; BINDING AFFINITY; CARDIOVASCULAR EFFECT; CATTLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG STRUCTURE; NONHUMAN;

EID: 0036033521     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. ++ channel blocker. Jpn J Pharmacol 1989; 51: 57-64.
2. Yagil Y, Lustig A. Azelnidipine (CS-905), a novel dihydropyridine calcium channel blocker with gradual onset and prolonged duration of action. Cardiovasc Drug Rev 1995; 13: 137-48.
3. Burges RA, Dodd MG, Gardiner DG. Pharmacologic profiles of amlodipine. Am J Cardiol 1989; 64: 101-181.
4. Stopher DA, Beresford AP, Macrae PV, Humphrey MJ. The metabolism and pharmacokinetics of amlodipine in humans and animals. J Cardiovasc Pharmacol 1988; 12 (Suppl 7): S55-S59
5. Nayler WG, Gu XH. The unique binding properties of amlodipine: A long acting calcium antagonist. J Hum Hypertens 1991; 5 (Suppl 1): 55-9.
6. Rhodes DG, Sarmiento JG, Herbette LG. Kinetics of binding of membrane-active drugs to receptor sites: Diffusion-limited rates for a membrane bilayer approach of 1,4-dihydropyridine calcium channel antagonists to their active site. Mol Pharmacol 1985; 27: 612-23.